CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ±èÁÖÇ×
  • ¾ÏÁ¤¹ÐÀÇ·á¼¾ÅÍÀå
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : Æó¾Ï, µÎ°æºÎ¾Ï, ½Äµµ¾Ï
  • Á÷ À§: ±³¼ö(¾ÏÁ¤¹ÐÀÇ·á¼¾ÅÍÀå)
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

µî·Ï

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ ´Ù¿î·Îµå
94 ÇØ¿Ü Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients  
93 ÇØ¿Ü High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma  
92 ÇØ¿Ü Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement  
91 ÇØ¿Ü A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer  
90 ÇØ¿Ü Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes  
89 ÇØ¿Ü Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan  
88 ÇØ¿Ü An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia  
87 ÇØ¿Ü Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib  
86 ÇØ¿Ü Analysis of Tumor Markers in the Cytological Fluid Obtained from Computed Tomography-Guided Needle Aspiration Biopsy for the Diagnosis of Non-small Cell Lung Cancer  
85 ÇØ¿Ü A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results  
ÀÌÀüÆäÀÌÁö À̵¿ 1 2 3 4 5 6 7 8 9 10 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729